Table 2.
Laboratory values after 12 weeks of treatment with different dosages of n3‐PUFA
| Placebo n = 16 | 1 g n3‐PUFA n = 12 | 4 g n3‐PUFA n = 12 | P‐value | |
|---|---|---|---|---|
| HDL inflammatory index | 0.67 (0.49‐1.04) | 0.71 (0.55‐1.01) | 0.98 (0.73‐1.16) | 0.018 |
| Haemoglobin, g/dL | 13.1 (12‐14.5) | 13.6 (12.3‐14) | 14.5 (12.4‐15.4) | 0.125 |
| NT‐proBNP, pg/mL | 2168 (1428‐2764) | 2301 (1268‐4825) | 3603 (903‐7111) | 0.158 |
| Total cholesterol, mg/dL | 169.5 (162.3‐190.00) | 175.5 (142‐201.8) | 166 (147.5‐189.3) | 0.686 |
| HDL, mg/dL | 45.5 (37.5 ‐54) | 48 (33.5‐56) | 39.5 (32.5‐43.8) | 0.741 |
| LDL, mg/dL | 99.2 (80.3‐114.9) | 96.5 (72.8‐125.4) | 107.7 (91.3‐124.4) | 0.304 |
| Triglycerides, mg/dL | 126 (106‐154) | 145 (118‐162) | 90 (67‐124) | 0.065 |
| CRP, mg/dL | 0.54 (0.23‐0.77) | 0.40 (0.21‐0.7) | 0.38 (0.28‐0.93) | 0.505 |
| Leukocytes, G/L | 6.4 (5.8‐7.8) | 5.7 (5.4‐8.3) | 7 (6.4‐8.2) | 0.437 |
| eGFR, mL/min/1.73 m2 | 63 (47‐71) | 49 (37‐61) | 54 (46‐67) | 0.339 |
| AST, U/L | 27 (24.00‐33) | 24 (21‐29) | 32 (27‐36) | 0.358 |
| ALT, U/L | 27 (21‐32) | 23. (17‐30) | 29 (24‐45) | 0.238 |
| Fibrinogen, mg/dL | 412 (372‐475) | 415 (357‐458) | 421 (387‐443) | 0.593 |
Numbers are median (interquartile range). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, c reactive protein; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; yGT, gamma‐glutamyl transpeptidase.